###begin article-title 0
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 407 412 407 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2</italic>
###xml 414 420 414 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
Excision repair cross-complementing group 1 (ERCC1) and group 2 (ERCC2), and X-ray repair cross-complementing group 1 (XRCC1) proteins play important roles in the repair of DNA damage and adducts. Single nucleotide polymorphisms (SNPs) of DNA repair genes are suspected to influence treatment effect and survival of cancer patients. This study aimed to investigate the relationship between polymorphisms in ERCC2, ERCC1 and XRCC1 genes and survival of non-smoking female patients with lung adenocarcinoma.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2</italic>
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method to evaluate SNPs in ERCC2, ERCC1 and XRCC1 genes among 257 patients.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 311 317 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 404 410 404 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 709 715 709 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 719 724 719 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 841 849 <span type="species:ncbi:9606">patients</span>
The overall median survival time (MST) was 13.07 months. Increasing numbers of either ERCC1 118 or XRCC1 399 variant alleles were associated with shorter survival of non-smoking female lung adenocarcinoma patients (Log-rank P < 0.001). The adjusted hazard ratios (HRs) for individuals with CT or TT genotype at ERCC1 Asn118Asn were 1.48 and 2.67 compared with those with CC genotype. For polymorphism of XRCC1 399, the HRs were 1.28 and 2.68 for GA and AA genotype. When variant alleles across both polymorphisms were combined to analysis, the increasing number of variant alleles was associated with decreasing overall survival. Using the stepwise Cox regression analysis, we found that the polymorphisms in ERCC1 and XRCC1, tumor stage and chemotherapy or radiotherapy status independently predicted overall survival of non-smoking female patients with lung adenocarcinoma.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms in ERCC1 and XRCC1 genes might be prognostic factors in non-smoking female patients with lung adenocarcinoma.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 720 721 720 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 722 723 722 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 884 885 884 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 886 887 886 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1187 1188 1187 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1385 1390 1385 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1</italic>
###xml 1405 1410 1405 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2</italic>
###xml 1459 1464 1459 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1467 1473 1467 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 1684 1690 1684 1690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 1870 1876 1870 1876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 2059 2065 2059 2065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 2185 2191 2185 2191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 2195 2201 2195 2201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 2239 2241 2239 2241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 2400 2406 2400 2406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 2572 2574 2572 2574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 2575 2577 2575 2577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 84 90 <span type="species:ncbi:9606">people</span>
###xml 256 261 <span type="species:ncbi:9606">women</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
###xml 969 977 <span type="species:ncbi:9606">patients</span>
###xml 1177 1185 <span type="species:ncbi:9606">patients</span>
###xml 1285 1293 <span type="species:ncbi:9606">patients</span>
###xml 2955 2963 <span type="species:ncbi:9606">patients</span>
Lung cancer is a major cause of cancer mortality worldwide, and more than a million people in the world die from the disease each year [1]. Adenocarcinoma accounts for about 25% to 40% of all lung cancers, and is now the most common form of lung cancer in women [2]. It is the most frequent subtype occurring in those who have never smoked. Five-year survival rate of lung cancer is at only 15% in the United States and even lower in China [3]. Genetic factors are considered to influence the treatment effectiveness of lung cancer [4], and thus affect the prognosis of patients. There are some molecular markers showing potential as therapeutic and prognostic indicators, but none could be used into clinical practice [5,6]. Of these factors, DNA repair capacity (DRC) is an important one. Several studies have shown associations between inefficient DNA repair and lung cancer risk [7,8]. It is also possible that individual DRC can affect the survival of lung cancer patients. It has been speculated that single nucleotide polymorphisms (SNPs) in DNA repair genes may change gene expression and activity, hence influence the effectiveness of cancer treatment and survival of patients [9]. To test above possibility, we assess the relationship between survival of lung adenocarcinoma patients and SNPs in three DNA repair genes, including excision repair cross-complementing group 1 (ERCC1) and group 2 (ERCC2), and X-ray repair cross-complementing group 1 (XRCC1). ERCC2 is located in chromosome 19q13.2-13.3 and codes for an evolutionarily conserved helicase, a subunit of TFIIH complex which is essential for transcription and nucleotide excision repair (NER). The common SNPs of ERCC2 gene is at codon 751 (A > C substitution at nucleotide position 35931, exon 23, Lys>Gln, rs13181) and codon 312 (G >A substitution at position 23951, exon 10, Asp>Asn, rs1799793). ERCC1 is also located in chromosome 19q13.2-13.3 and codes for a leading protein in NER, responsible for recognition of DNA damage and removal of the damaged nucleotides. The common SNP of ERCC1 gene is at codon 118 (C > T substitution at exon 4, without amino acid change--Asn/Asn, rs11615). The study showed that ERCC1 and ERCC2 mRNA levels were correlated with DRC [10]. XRCC1 protein plays a central role in base excision repair (BER) pathway by interacting with other DNA repair proteins. The most extensively studied SNP of XRCC1 gene is at codon 399 (G > A substitution at position 28152, exon 10, Arg>Gln, rs25487), which has been reported to be associated with an altered DNA repair activity [11,12]. SNP analyzing involves little more than a blood sample and relatively simple and precise polymerase chain reaction (PCR)-based techniques, making it more practical in the clinical testing than many other studied prognostic markers. Therefore, in this study we prospectively assess the relationship between the four SNPs in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.
###end p 10
###begin title 11
Methods
###end title 11
###begin title 12
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient recruitment and follow-up
###end title 12
###begin p 13
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 139 144 <span type="species:ncbi:9606">human</span>
###xml 281 292 <span type="species:ncbi:9606">participant</span>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
###xml 540 551 <span type="species:ncbi:9606">participant</span>
###xml 687 695 <span type="species:ncbi:9606">patients</span>
###xml 886 898 <span type="species:ncbi:9606">participants</span>
###xml 962 970 <span type="species:ncbi:9606">patients</span>
###xml 1068 1076 <span type="species:ncbi:9606">patients</span>
All patients were from the ongoing study of lung cancer in non-smoking females, which started from July, 1999 in Shenyang city, China. The human investigations were approved by the Institutional Review Board of China Medical University, and informed consent was obtained from each participant or their representatives if direct consent could not be obtained. All patients were unrelated ethnic Han Chinese. Individual with a total of 100 cigarettes in his lifetime was defined as a smoker, otherwise he was considered as a non-smoker. Each participant donated 10 ml venous blood and was interviewed to collect demographic data and clinical information. For this study, we identified 285 patients who were diagnosed with histologically confirmed lung adenocarcinoma (stage I-IV) between the years 1999 and 2004. The year 2004 was chosen as the last year of eligibility in order that all participants have adequate follow-up. About the histological subtype of 285 patients, 228 were diagnosed using surgical specimen and 57 using exfoliated cells of lung adenocarcinoma patients whose tumor stages were determined by thoracic imageology.
###end p 13
###begin p 14
###xml 326 334 <span type="species:ncbi:9606">patients</span>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
Dates of death were obtained using at least one of the four following methods: inpatient and outpatient medical records, the registry of causes of death in Shenyang Center for Disease Control and Prevention (CDC), registration and presumption of death in Shenyang Public Security Bureau, and telephone follow-up. Twenty eight patients were lost to follow up. However, there was no significant difference in the characteristics between the patients with and without follow-up information. Finally, 257 patients were included in this analysis.
###end p 14
###begin title 15
DNA extraction and genotyping
###end title 15
###begin p 16
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 329 335 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 354 360 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 823 829 823 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 845 851 845 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 868 874 868 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 893 899 893 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 966 974 <span type="species:ncbi:9606">patients</span>
###xml 1005 1012 <span type="species:ncbi:9606">persons</span>
Genomic DNA samples were extracted by guanidine hydrochloride (GuHCl) method. SNP was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method as described previously [13]. The PCR primers (Takara Biotechnology Dalian Co. Ltd., China) for amplifying DNA fragment containing the ERCC2 751, ERCC2 312, ERCC1 118 and XRCC1 399 sites were 751 F5'-GCC CGC TCT GGA TTA TAC G-3' and R5'-CTA TCA TCT CCT GGC CCC C-3', 312 F5'-CTG TTG GTG GGT GCC CGT ATC TGT TGG TCT-3' and R5'-TAA TAT CGG GGC TCA CCC TGC AGC ACT TCC T-3', 118 F5'-AGG ACC ACA GGA CAC GCA GA-3' and R5'-CAT AGA ACA GTC CAG AAC AC-3', 399 F5'-TTG TGC TTT CTC TGT GTC CA-3' and R5'-TCC TCC AGC CTT TTC TGA TA-3', respectively. The PCR products were digested with restriction enzyme (New England Biolabs, Beverly, MA) PstI (for ERCC2 751), StyI (for ERCC2 312), BsrdI (for ERCC1 118) and MspI (for XRCC1 399) to determine the genotypes. A 10% masked and random sample of patients was tested twice by different persons, and the results were found to be concordant for all of the masked duplicate sets.
###end p 16
###begin title 17
Statistical analysis
###end title 17
###begin p 18
The associations between overall survival and demographic characteristics, clinical features, and genetic SNPs were estimated using the Kaplan-Meier method and Log-rank test. Survival time was calculated from the date of cancer diagnosis to the date of death or last follow-up. In some analyses, we combined the heterozygous genotype with the homozygous rare genotype as the particular group in order to increase sample size. Univariate and multivariable Cox proportional hazards regression models were performed to estimate crude hazard ratio (HR) or adjusted HR and their 95% confidence intervals (CIs). The stepwise Cox regression model was also used to determine factors predictive of cancer prognosis, with a significant level of P < 0.05 for entering and P > 0.10 for removal of the variables. All the statistical analyses were performed using Statistical Product and Service Solutions (SPSS) v13.0.
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 20
###begin p 21
###xml 185 186 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 277 278 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
###xml 509 517 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
The mean age of patients was 51.16 +/- 9.48 years (range 18-75 years). The distribution of characteristics and clinical features of 257 lung adenocarcinoma patients were shown in Table 1. There were 206 deaths. The overall median survival time (MST) was 13.07 months. As Table 1 showed, patients with advanced cancer or without surgical operation had significantly shorter MSTs (Log-rank P < 0.05). Univariate Cox regression analysis suggested that the risks of death of lung adenocarcinoma were increased in patients with stage II, III and IV compared with those with stage I (HRs were 2.48, 3.46 and 4.66, respectively). The result also showed that the patients undergoing surgical operation had a decreased risk of death (HR = 0.61).
###end p 21
###begin p 22
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics and clinical features
###end p 22
###begin p 23
Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
###end p 23
###begin title 24
Genotype frequencies of genetic polymorphisms
###end title 24
###begin p 25
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 258 264 258 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 282 288 282 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Table 2 showed the genotype frequencies of four SNPs in 257 patients. All genotype frequencies of these four polymorphisms were found to be in Hardy-Weinberg equilibrium. The variant allele frequencies were 13.0% for ERCC2 751, 5.6% for ERCC2 312, 27.2% for ERCC1 118 and 34.6% for XRCC1 399 polymorphism. No associations were found between genotypes and age, tumor stage, surgical operation, chemotherapy or radiotherapy (data not shown).
###end p 25
###begin p 26
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms in DNA repair genes and survival of patients
###end p 26
###begin p 27
Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
###end p 27
###begin p 28
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
AHR adjusted for age, stage, surgical operation and chemotherapy or radiotherapy.
###end p 28
###begin p 29
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</sup>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
BLog-rank P and HR were calculated compared with wild genotype(AA) of ERCC2 751 polymorphism.
###end p 29
###begin p 30
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
CLog-rank P and HR were calculated compared with wild genotype(GG) of ERCC2 312 polymorphism.
###end p 30
###begin title 31
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms and survival of patients
###end title 31
###begin p 32
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 589 595 589 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 144 152 <span type="species:ncbi:9606">Patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
The associations between genotypes of four SNPs and survival of non-smoking female patients with lung adenocarcinoma were suggested in Table 2. Patients with CT or TT genotype at ERCC1 Asn118Asn showed significantly shorter survival time than those with CC genotype (11.07, 6.20 months versus 17.23 months) (Log-rank test, P < 0.001). In terms of XRCC1 399 polymorphism, the difference in the MSTs among patients with GG (19.10 months), GA (10.40 months) and AA (9.23 months) was statistically significant (Log-rank test, P < 0.001). However no associations were found between two SNPs of ERCC2 gene and the overall survival of patients.
###end p 32
###begin p 33
###xml 337 343 337 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 356 362 356 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 483 489 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 593 599 593 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 828 834 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 617 625 <span type="species:ncbi:9606">patients</span>
In the further analysis, lung adenocarcinoma patients were stratified by stage. There were no significant differences in survival times of stage I-II patients with variant genotypes of four SNPs. For patients with stage III or IV, Kaplan-Meier analyses proved that individuals with heterozygous variant or homozygous variant genotype at ERCC1 Asn118Asn or XRCC1 Arg399Gln had shorter MSTs than those with wild genotype (Figure 1). The MSTs of patients with CC, CT and TT genotype at ERCC1 Asn118Asn were 14.53, 9.57 and 5.03 months and the difference was significant (Log-rank P < 0.001). For XRCC1 399 polymorphism, patients with GA or AA genotype lived shorter than those with GG genotype and corresponding MSTs were 9.57, 4.27 and 14.20 months(Log-rank P < 0.001). There were no differences in MSTs according to genotypes of ERCC2 751 or 312 polymorphism.
###end p 33
###begin p 34
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 0 105 0 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kaplan-Meier curves for patients with stage III-IV by (A) <italic>ERCC1 </italic>118 genotypes and (B) <italic>XRCC1 </italic>399 genotypes</bold>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier curves for patients with stage III-IV by (A) ERCC1 118 genotypes and (B) XRCC1 399 genotypes.
###end p 34
###begin p 35
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 312 318 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 454 460 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
In the Cox regression model, after adjusting for age, tumor stage, surgical operation and chemotherapy or radiotherapy, variant genotypes of ERCC1 118 or XRCC1 399 polymorphism were associated with higher risks of death for non-smoking female patients with lung adenocarcinoma (Table 2). With the CC genotype at ERCC1 Asn118Asn being the reference, the HR for CT genotype was 1.48 (P = 0.009) compared to 2.67 (P < 0.001) in the TT genotype. In terms of XRCC1 399 polymorphism, we found that compared with those carrying GG genotype, the HRs were 1.28 (P = 0.109) and 2.68 (P < 0.001) for individuals with GA and AA genotype, respectively.
###end p 35
###begin p 36
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
In addition to evaluating the genetic polymorphisms separately, we studied the association between patients' survival and the total number of variant alleles of ERCC1 and XRCC1 polymorphisms (Table 3). In the double homozygous group (0 variant allele), the overall MST was 25.10 months. As the number of variant alleles increased, the MSTs decreased to 13.07, 9.27, 6.30 and 3.87 months. The Log-rank test was statistically significant (P < 0.001). The HRs for individuals with 1, 2, 3, 4 variant allele(s) were 1.52, 2.33, 2.98 and 9.24 compared with those carrying 0 variant allele. Besides, the effect was also conspicuous for the patients with stage III-IV (Log-rank P < 0.001) but not significant for those with stage I-II (P = 0.145).
###end p 36
###begin p 37
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms in combination of ERCC1 and XRCC1 and survival of patients
###end p 37
###begin p 38
Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
###end p 38
###begin p 39
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
aHR adjusted for age, stage, surgical operation and chemotherapy or radiotherapy.
###end p 39
###begin p 40
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
bMST for this genotype could not be calculated.
###end p 40
###begin p 41
###xml 176 182 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 190 196 190 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Furthermore we evaluated an interaction effect of the two SNPs on the survival of non-smoking female patients with lung adenocarcinoma. We found that individuals carrying both ERCC1 118 and XRCC1 399 variant alleles were at a higher death risk of lung adenocarcinoma than those with only one of them (adjusted HRs were 2.44, 1.79 and 1.64, respectively) (Table 4).
###end p 41
###begin p 42
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
Interaction of ERCC1 and XRCC1 polymorphisms on survival of lung adenocarcinoma
###end p 42
###begin p 43
Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
###end p 43
###begin p 44
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
AHR and 95%CI were calculated by Cox regression, with the ERCC1 wild genotype (CC) and XRCC1 wild genotype (GG) as the reference group;HRs were adjusted for age, stage, surgical operation and chemotherapy or radiotherapy.
###end p 44
###begin p 45
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 304 310 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
Stepwise Cox proportional hazard analysis was used to study the relationship between factors including demographic characteristics, clinical features and genetic SNPs and survival of non-smoking female patients with lung adenocarcinoma. Four variables (stage, chemotherapy or radiotherapy, ERCC1 118 and XRCC1 399 polymorphisms) were included in the Cox regression model (Table 5).
###end p 45
###begin p 46
Stepwise Cox regression analysis on survival of lung adenocarcinoma
###end p 46
###begin p 47
Abbreviation: SEM, Standard error of difference; HR, hazard ratio; CI, confidence interval.
###end p 47
###begin p 48
beta, regression coefficient.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 642 648 642 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 661 667 661 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 834 840 834 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
###xml 248 253 <span type="species:ncbi:9606">women</span>
###xml 773 778 <span type="species:ncbi:9606">women</span>
In this study, we explored the relationship between SNPs of three DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma in China. In WHO Western Pacific Region, lung cancer was the commonest cancer cause of death in women and the proportion of adenocarcinoma in lung cancer has increased quickly in both genders over the last few decades [14]. So we focused our study on lung adenocarcinoma in females who were requested to be non-smokers in order to control the confounding influence of smoking. This study showed that being advanced stage, without chemotherapy or radiotherapy, carrying variant genotypes at ERCC1 Asn118Asn or XRCC1 Arg399Gln were proved to be unfavorable prognostic factors for lung adenocarcinoma in Chinese non-smoking women. However, the associations have not been found between ERCC2 751 or 312 polymorphism and survival of lung adenocarcinoma.
###end p 50
###begin p 51
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 207 213 207 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 426 432 426 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 625 631 625 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 499 504 <span type="species:ncbi:9606">women</span>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
The XRCC1 protein is considered to play an important role in both base excision repair and single-strand break repair. XRCC1 Arg399Gln polymorphism was the commonest one among more than 60 validated SNPs in XRCC1 gene and showed no major variations by ethnicity [15]. This polymorphism has been suggested to be a risk factor for the development of lung cancer [16-20]. In our previous study, a significant association between XRCC1 399Gln/Gln genotype and risk of lung cancer in Chinese non-smoking women was found [21]. In the present study, we found that non-smoking female lung adenocarcinoma patients with AA genotype at XRCC1 Arg399Gln had a shorter survival time (9.23 months vs. 19.10 months) and higher risk of death (adjusted HR = 2.68, 95%CI = 1.79-4.02) than those with GG genotype. It is consistent with other studies, although those results were obtained from the subjects of all genders, smoking status and histopathologic subtypes [22-24].
###end p 51
###begin p 52
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 421 427 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 653 659 653 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 814 820 814 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 893 901 <span type="species:ncbi:9606">patients</span>
As for ERCC1 Asn118Asn polymorphism, we observed that the patients with CT or TT genotype showed a significantly shorter survival time than those with CC genotype (11.07 and 6.20 versus 17.23 months). In the multivariable Cox regression, ERCC1 118 variant genotype (CT/TT) remained prognostic factors of lung adenocarcinoma (HR = 1.60, P value = 0.001). To date, only a few studies have examined the relationship between ERCC1 polymorphism and survival of lung cancer, and they didn't control the influence of gender, smoking status and histopathologic subtypes [25-27]. In terms of chemotherapy response, a few studies suggested an association between ERCC1 Asn118Asn polymorphism and response to platinum-based treatment of lung cancer [25,27,28]. Although these studies have shown possible relationship between ERCC1 polymorphism and effectiveness of cancer treatment or survival of cancer patients, the biological effect of this synonymous SNP is unclear.
###end p 52
###begin p 53
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC2 </italic>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
In our study, no associations were found between the overall survival and two SNPs of ERCC2 gene. This is consistent with other studies [22,25,29], but there are studies showing an opposite effect [24]. The explanation for these discordant results remains to be elucidated.
###end p 53
###begin p 54
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 442 450 <span type="species:ncbi:9606">patients</span>
Many clinical features may play important roles in the survival of cancer patients. The multivariable Cox regression in this study showed that being advanced stage (III+IV) and without chemotherapy or radiotherapy treatment were independent unfavorable prognostic factor for lung adenocarcinoma in non-smoking female population. Surgical status wasn't included in the stepwise Cox model maybe because the surgical treatment is decided by the patients' conditions such as tumor stage and histopathologic subtypes, so the surgical status may be a dependent variable but not an independent prognostic factor.
###end p 54
###begin p 55
Genetic polymorphisms as either prognostic or predictive biomarkers have many advantages, especially in the advanced cancer setting. First of all, the biological specimen for detecting SNP is easily to obtain. Second, the detecting method is simple, precise and practical. Finally, in the advanced cancer setting, diagnoses are made using specialized and mostly body-harmed method; otherwise SNP detecting can avoid these problems.
###end p 55
###begin p 56
###xml 295 301 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 315 321 315 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
In conclusion, this study analyzed four SNPs in three DNA repair genes in relation to survival of non-smoking female patients with lung adenocarcinoma in China. The results suggested that besides clinical features such as tumor stage and chemotherapy or radiotherapy treatment, polymorphisms of ERCC1 Asn118Asn and XRCC1 Arg399Gln were associated with survival of patients. Because DNA repair is a complex system including many pathways and genes, larger studies with more genetic polymorphisms, even haplotypes, in different ethnic populations and the functional or biological relevance of these polymorphisms are needed to confirm our conclusions.
###end p 56
###begin title 57
Conclusions
###end title 57
###begin p 58
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC1 </italic>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1 </italic>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms in ERCC1 and XRCC1 genes might be prognostic factors in non-smoking female patients with lung adenocarcinoma.
###end p 58
###begin title 59
Competing interests
###end title 59
###begin p 60
The authors declare that they have no competing interests.
###end p 60
###begin title 61
Authors' contributions
###end title 61
###begin p 62
ZY, BZ, ML, and PG performed the analysis, interpreted the data and drafted the manuscript. BZ, QH, and ZC contributed to the design and coordination of the study and helped to draft the manuscript. XLL, RM, WB, SX, YJ, SX, YL, and XL participated in data collection, DNA isolation and interpreted the data. XX, XLL, ZY and MS participated in SNP genotyping and revised the manuscript. All authors read and approved the final manuscript.
###end p 62
###begin title 63
Pre-publication history
###end title 63
###begin p 64
The pre-publication history for this paper can be accessed here:
###end p 64
###begin p 65

###end p 65
###begin title 66
Acknowledgements
###end title 66
###begin p 67
###xml 19 27 <span type="species:ncbi:9606">patients</span>
We are grateful to patients for their participation. We would like to thank all the personnel at the hospitals and Shenyang CDC in our study. This study was supported by National Natural Science Foundation of China (No. 30471493), Natural Science Foundation of Liaoning Province (No. 20072103), Provincial Education Department of Liaoning (No. 2008S232) and China Medical Board (No. 00726).
###end p 67
###begin article-title 68
The world health report 2002---reducing risks, promoting healthy life
###end article-title 68
###begin article-title 69
Pathologic evaluation of lung cancer
###end article-title 69
###begin article-title 70
Global cancer statistics, 2002
###end article-title 70
###begin article-title 71
The role of p53 in treatment responses of lung cancer
###end article-title 71
###begin article-title 72
Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets
###end article-title 72
###begin article-title 73
A translational view of the molecular pathogenesis of lung cancer
###end article-title 73
###begin article-title 74
###xml 10 17 <span type="species:ncbi:4097">tobacco</span>
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study
###end article-title 74
###begin article-title 75
Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis
###end article-title 75
###begin article-title 76
Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer
###end article-title 76
###begin article-title 77
DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes
###end article-title 77
###begin article-title 78
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 122 129 <span type="species:ncbi:4097">tobacco</span>
The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK
###end article-title 78
###begin article-title 79
XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects
###end article-title 79
###begin article-title 80
Relationship between ERCC2 polymorphism and risk of lung cancer in Chinese nonsmoker
###end article-title 80
###begin article-title 81
Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review
###end article-title 81
###begin article-title 82
Polymorphisms of DNA repair genes and risk of non-small cell lung cancer
###end article-title 82
###begin article-title 83
Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China
###end article-title 83
###begin article-title 84
Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk
###end article-title 84
###begin article-title 85
Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk
###end article-title 85
###begin article-title 86
Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer
###end article-title 86
###begin article-title 87
###xml 65 70 <span type="species:ncbi:9606">women</span>
XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers
###end article-title 87
###begin article-title 88
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India
###end article-title 88
###begin article-title 89
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer
###end article-title 89
###begin article-title 90
###xml 98 106 <span type="species:ncbi:9606">patients</span>
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
###end article-title 90
###begin article-title 91
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy
###end article-title 91
###begin article-title 92
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
###end article-title 92
###begin article-title 93
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer
###end article-title 93
###begin article-title 94
Genetic polymorphisms and treatment response in advanced non-small cell lung cancer
###end article-title 94
###begin article-title 95
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer
###end article-title 95

